Eye disease and visual impairment are common in the elderly and are associated with social and functional decline, the need to access community support services, depression, falls, nursing home placement and increased mortality.
To provide guidance for general practitioners in the detection and recommended management of the most important eye conditions in the elderly in Australia: refractive error, cataract, diabetic retinopathy, age-related macular degeneration and glaucoma.
Timely detection and treatment of eye disease can greatly reduce its morbidity. Elderly patients should be encouraged to undergo eye testing every 2 years. Health professionals, including general practitioners, optometrists and ophthalmologists should work collaboratively to ensure patients have access to appropriate disease detection and treatment.
Eye disease and visual impairment are frequently encountered in the elderly population. Although ophthalmic pathology is very rarely life threatening and may not be at the forefront of medical professionals’ minds when seeing elderly patients, the consequences of visual impairment are wide-ranging. Visual impairment may be associated with social and functional decline,1 use of community support services,2,3 depression,4 falls,5–7 nursing home placement 8 and increased mortality.1,9,10
Australia has good epidemiological data concerning eye disease and visual loss from two large cross-sectional, population-based studies: the Melbourne Visual Impairment Project and the Blue Mountains Eye Study, which together have provided data on nearly 9000 participants. These studies highlight an exponential increase in visual loss with increasing age: the estimated prevalence of low vision (worse than 6/12, or driving vision) and blindness (worse than 6/60) increased from 11% and 0.7%, respectively, in people aged 70–79 years, up to 39% and 17%, respectively, in those aged >90 years.11
There are numerous potential causes of visual loss; however, this article aims to highlight the areas of greatest relevance to and encountered most frequently in the elderly, namely refractive error, cataracts, age-related macular degeneration, diabetic retinopathy and glaucoma.
Uncorrected refractive error may be perceived as primarily a problem in the developing world, but it still remains highly relevant in developed countries. A study combining the datasets from the Melbourne Visual Impairment Project and the Blue Mountains Eye Study concluded that 62% of low vision and 4% of blindness in Australia were attributable to refractive error alone.11
Barriers to refractive correction in the elderly may be social, financial, cognitive or logistical if living in isolated rural communities or nursing homes. Refractive error can be identified in patients presenting with reduced vision by testing for improvement of visual acuity with a pinhole. Although non-correctable visual impairment has the greatest impact on individuals, visual impairment resulting from refractive error has still been shown to affect physical and social functioning.12 In a randomised controlled trial assessing the impact of immediate refractive correction on nursing home residents, Owsley et al found significant improvements in reading, psychological distress, activities and hobbies, and social interaction.13
When vision cannot be improved by refraction, the next consideration for the elderly should be the possibility that cataracts have developed. Cataracts represent the leading cause of blindness worldwide and are extremely common with increasing age. In a cohort of the Melbourne Visual Impairment Project investigating visual impairment in elderly institutionalised Australians, the prevalence of cataract or previous need for cataract surgery increased from 56% in those aged 70–79 years to 97.5% in people aged ≥90 years.14 Age is not a barrier to consideration of cataract surgery, which should be considered for any patient who has a problem with visual function or performing activities of daily living, and wishes to improve their vision with surgical intervention. As approximately 95% of cataract surgery is performed under local anaesthetic,15 medical comorbidities are less critical than for most operations.
Medical problems of most relevance are head tremor, the inability to lie relatively flat without excessive shortness of breath, and cognitive status such that the patient is unable to remain still for about 20 minutes for the operation. If these situations arise, surgery under general anaesthetic may be offered, subject to anaesthetic fitness for surgery. Uncontrolled hypertension may also prohibit surgery, requiring liaison with the GP for optimal control of blood pressure.
A large proportion of elderly patients are on systemic anticoagulant or antiplatelet medications: a multicentre audit of 55,567 cataract operations in 2009 found that one-third of patients were taking aspirin, warfarin, clopidogrel or dipyridamole.16 No increase in potentially sight-threatening complications was identified in these patients; these medications are not prohibitive to pursuing cataract surgery.
A study assessing the impact of cataract surgery on health-related quality of life in nursing home residents found that as well as improvement in visual acuity, patients showed significant improvement in psychological distress and social interaction after undergoing cataract surgery.17
Age-related macular degeneration
Although data from the Blue Mountains Eye Study found that cataracts were the leading cause of visual impairment in the older population, age-related macular degeneration (AMD) represented the principal cause of blindness. AMD is broadly divided into two types: dry AMD and wet AMD, although the former may progress to the latter.
The clinical presentation of dry AMD is usually a gradual deterioration of vision in one or both eyes and increasing difficulty with tasks such as reading and driving. A more acute loss of central vision with metamorphopsia (distortion of straight lines) is suggestive of wet AMD. The diagnosis may be confirmed with dilated slit-lamp examination, optical coherence tomography (OCT) scans (Figure 1) and fluorescein angiography of the fundus, People with symptoms suggestive of wet AMD should be referred urgently for ophthalmic assessment as there is the potential for rapid progression and irreversible damage in wet AMD.
Figure 1. OCT scans
A. Arrow indicates a normal foveal contour
B. Arrow indicates the presence of sub-retinal fluid in wet AMD
Currently, there is no treatment to improve vision in dry AMD, although smokers should be advised to stop smoking to reduce the risk of progression. The AREDS study found that taking antioxidant supplements (vitamin A, vitamin C and beta carotene) combined with zinc and copper modestly reduces the risk of progression of AMD in certain subgroups of patients.18 It is known, however, that beta-carotene may increase the risk of lung cancer in smokers and the more recent AREDS2 trial, therefore, found that it may be more appropriate to substitute lutein and zeaxanthin for beta-carotene in the supplements.19
For most people with wet AMD, the treatment involves intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents. These agents have revolutionised the management and visual prognosis of wet AMD over the last decade and frequently, patients’ vision will be stabilised or improved with treatment. Anti-VEGF agents include ranubizimab, which may need to be given at up to monthly intervals, or more recently, the alternative aflibercept, which can reduce the frequency of injections to every two months. The frequency of follow-up and intravitreal injections may represent significant logistical challenges for some elderly patients. Consideration is given to stopping treatment in the presence of significant visual deterioration despite optimum treatment, macular fibrosis/scarring or failure of the visual acuity to improve despite resolution of sub/intra-retinal fluid with treatment.
Despite the profound loss of central visual acuity that may result from AMD, the condition spares the peripheral retina and fortunately, therefore, many patients are able to maintain an independent lifestyle using their peripheral vision. Vision Australia and other low vision services enable patients to access advice and visual aids to assist them in their activities of daily living and maintain independence.
All people with diabetes mellitus are at risk of developing diabetic retinopathy (Figure 2). Given the increasing prevalence of diabetes and an ageing population, diabetic retinopathy will affect an increasing number of elderly people. The AusDiab Study Group concluded that 15% of people with diabetes have diabetic retinopathy.20 The Australian National Health and Medical Research Council (NHMRC) recommends that all people with diabetes, including those who do not have diabetic retinopathy, should have a dilated fundal examination at least every 2 years.21 If diabetic retinopathy is detected, examinations should be performed at least annually thereafter, with greater frequency according to the severity.
Figure 2. Diabetic retinopathy showing widespread retinal haemorrhages and hard exudates
It should be emphasised that, aside from ophthalmological treatment, good glycaemic, lipid and hypertensive control will all reduce development and progression of diabetic retinopathy22–25 and patients should liaise with their GP for optimal management of these risk factors.
In the presence of diabetic retinopathy (Figure 2) , visual loss may result from macular oedema or proliferative diabetic retinopathy, causing vitreous haemorrhage or tractional retinal detachment. Diabetic macular oedema is managed with focal laser treatment to areas of leakage and, increasingly, adjunctive intravitreal anti-VEGF agents, such as those used in wet AMD. Proliferative diabetic retinopathy is managed with pan-retinal photocoagulation laser, which reduces the angiogenic drive from ischaemic retina with subsequent regression of the new vessel growth. Vitrectomy surgery may be performed for removal of vitreous haemorrhage, relief of retinal traction and internal completion of pan-retinal laser.
Chronic open-angle glaucoma
Chronic open-angle glaucoma is an intraocular pressure (IOP)-related progressive optic neuropathy with accompanying characteristic changes in the optic nerve and visual field (Figure 3). The Blue Mountains Eye Study found a 3% prevalence of open-angle glaucoma in people aged >49 years, but an exponential rise in prevalence was observed with increasing age.26 Glaucomatous damage of the optic nerve can cause irreversible visual field loss, which, if untreated, may progress to complete blindness; the aim of treatment, therefore, is to prevent visual disability during a person’s lifetime, or progression of disability if this has occurred. Currently, the only established treatment for glaucoma is lowering the IOP and this is most commonly achieved medically; alternatives are laser (trabeculoplasty of the trabecular meshwork or cyclodiode of the ciliary body) or surgical treatment.
Figure 3. Advanced cupping of the optic nerve in glaucoma
When topical treatment is prescribed for the elderly, consideration should be given to the most appropriate agent. Prostaglandin analogues are the most commonly used first-line treatment. They are generally well tolerated and have few systemic side effects. Topical beta-blockers should be avoided in people with severe hypotension, obstructive airways disease, uncontrolled cardiac failure, bradycardia or second/third-degree atrioventricular block. Alpha-adrenoceptor agonists (eg. brimonidine) are unsuitable for patients with severe cardiovascular disease and may interact with monoamine oxidase inhibitors and tricyclic antidepressants. Carbonic anhydrase inhibitors (eg. brinzolamide, dorzolamide) should be used with caution in people with renal impairment. Laser treatment may be more appropriate in patients who cannot be adequately and safely treated with eyedrops, are unable to instil eyedrops, or are not compliant with treatment because of cognitive impairment.
Good communication between primary and secondary care providers is key in ensuring that treatment and management decisions are appropriate and include consideration of comorbidities and lifetime expectancy. Patients with established glaucoma almost invariably require lifelong follow-up in view of the potential for irreversible visual loss, although the frequency of review should be informed by the patient’s age, life expectancy and the extent and, critically, the rate of progression of visual field loss.
Many ophthalmic problems may be encountered in the elderly, but refractive error, cataract, AMD, diabetic retinopathy and chronic open-angle glaucoma represent the most common conditions and the principal causes of visual impairment in the elderly. As demographic ageing of the population occurs, the burden of these diseases will continue to rise as the number of people suffering from impaired vision and blindness increases.
Even in the absence of established pathology, elderly people should be advised to have an eye examination at least every 2 years so that eye disease, which is often asymptomatic, may be detected and treated, thereby preventing further visual loss. Many elderly people regard deteriorating vision as an inevitable sign of ageing – this is not the case and timely intervention may help prevent loss of sight and the associated negative impact on quality of life that this brings.
Jonathan Goodfellow acknowledges financial assistance from HCA International Foundation in supporting his fellowship training.
Conflict of interests: None.
Provenance and peer review: Commissioned; externally peer reviewed.
- Jacobs JM, Hammerman-Rozenberg R, Maaravi Y, Cohen A, Stessman J. The impact of visual impairment on health, function and mortality. Aging Clin Exp Res 2005;17:281–86.
- Wang JJ, Mitchell P, Smith W, Cumming RG, Attebo K. Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999;40:12–19.
- Wang JJ, Mitchell P, Smith W, Leeder SR. Factors associated with use of community support services in an older Australian population. Aust N Z J Public Health 1999;23:147–53.
- Rovner BW, Ganguli M. Depression and disability associated with impaired vision: the MoVies project. J Am Geriatr Soc 1998;46:617–19.
- Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58–64.
- Campbell AJ, Reinken J, Allan BC, Martinez GS. Falls in old age: a study of frequency and related clinical factors. Age Ageing 1981;10:264–70.
- Jack CI, Smith T, Neoh C, Lye M, McGalliard JN. Prevalence of low vision in elderly patients admitted to an acute geriatric unit in Liverpool: elderly people who fall are more likely to have low vision. Gerontology 1995;41:280–85.
- Mitchell P, Hayes P, Wang JJ. Visual impairment in nursing home residents: the Blue Mountains Eye Study. Med J Aust 1997;166:73–76.
- Klein R, Klein BEK, Moss SE. Age-related eye disease and survival: The Beaver Dam Eye Study. Arch Ophthalmol 1995;113:333–39.
- Wang JJ, Mitchell P, Simpson JM, Cumming RG, Smith W. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001;119:1186–90.
- Taylor HR, Keefe JE, Vu HTV, et al. Vision loss in Australia. Med J Aust 2005;182:565–68.
- Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RR, Mitchell P. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004;45:71–76.
- Owsley C, McGwin G Jr, Scilley K, Meek GC, Seker D, Dyer A. Effect of refractive error correction on health-related quality of life and depression in older nursing home residents. Arch Ophthalmol 2007;125:1471–77.
- VanNewkirk MR, Weih L, McCarty CA, Stanislavsky YL, Keefe JE, Taylor HR. Visual impairment and eye diseases in elderly institutionalized Australians. Ophthalmology 2000;107:2203–08.
- El-Hindy N, Johnston RL, Jaycock P, et al. The Cataract National Dataset Electronic Multicentre Audit of 55,567 operations: anaesthetic techniques and complications. Eye 2009;23:50–55.
- Benzimra JD, Johnston RL, Jaycock P, et al. The Cataract National Dataset Electronic Multicentre Audit of 55,567 operations: antiplatelet and anticoagulant medications. Eye 2009;23:10–16.
- Owsley C, McGwin G Jr, Scilley K, Meek GC, Seker D, Dyer A. Impact of cataract surgery on health-related quality of life in nursing home residents. Br J Ophthalmol 2007;91:1359–63.
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: report no 8. Arch Ophthalmol 2001;119:1417–36.
- Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005–15.
- Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003;26:1731–37.
- National Health and Medical Research Council. Guidelines for the management of diabetic retinopathy. Canberra: Commonwealth of Australia. Available at www.nhmrc.gov.au/_ files_nhmrc/publications/attachments/ di15.pdf [Accessed 20 June 2014].
- UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
- Stratton IM, CullCA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes; a prospective observational study (UKPDS 75). Diabetologia 2006;49:1761–69.
- Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631–40.
- ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233–44.
- Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661–69.